Soto-Mota Adrian, Carrillo-Larco Rodrigo, Gregg Edward, Rojas-Martínez Rosalba, Ezzati Majid, Aguilar-Salinas Carlos
Metabolic Diseases Research Unit, National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Mexico.
Tecnologico de Monterrey, School of Medicine, Mexico City, Mexico.
J Clin Endocrinol Metab. 2025 Mar 11. doi: 10.1210/clinem/dgaf158.
There is large variation in the individual risk of developing obesity-associated comorbidities. While obesity is highly prevalent in Mexico, data on the extent and heterogeneity of its associated co-morbidities is lacking. Hereby, we estimated the prevalence of different obesity-associated comorbidities, and how they have changed over 15 years.
We gathered data from different editions of nationally representative health and nutrition surveys (ENSANUT) from 2006 to 2022. The prevalence of obesity and the coexistence with diabetes, dyslipidemia, hypertension, depression, and impaired mobility, which are outcomes used in the Edmonton Obesity Staging System (EOSS) which assesses three dimensions (medical, mental, and functional) across five incremental severity stages, by sex and age groups were estimated across all included surveys. Metabolically healthy obesity was defined as the absence of diabetes, dyslipidemia and hypertension.
20758 participants were analyzed. Mean BMI increased progressively at all ages from 30.2 to 31.0 across survey rounds. Depression and impaired mobility were highly prevalent even among metabolically healthy obese individuals. While most people with obesity had at least one detectable abnormality, there was large heterogeneity in the presented comorbidities. The most prevalent EOSS categories were stage 2 for the medical dimension (90.1%), and stage 1 for the functional and mental dimensions (75.1% and 62.9%, respectively). The prevalence of obesity-related comorbidities increased with age but was similar across all surveys. In both sexes, metabolically healthy obesity was less likely as age and BMI increased.
The prevalence of obesity comorbidities has been stable over time in Mexico but increases with age. The rising prevalence of obesity and the ageing of the population will cause additional burdens to the population and the health system.
个体发生肥胖相关合并症的风险存在很大差异。虽然肥胖在墨西哥非常普遍,但缺乏关于其相关合并症的范围和异质性的数据。在此,我们估计了不同肥胖相关合并症的患病率,以及它们在15年中的变化情况。
我们收集了2006年至2022年不同版本的具有全国代表性的健康与营养调查(ENSANUT)的数据。在所有纳入的调查中,按性别和年龄组估计肥胖患病率以及与糖尿病、血脂异常、高血压、抑郁症和行动能力受损的共存情况,这些是埃德蒙顿肥胖分期系统(EOSS)中使用的结果,该系统在五个递增的严重程度阶段评估三个维度(医学、心理和功能)。代谢健康肥胖被定义为不存在糖尿病、血脂异常和高血压。
对20758名参与者进行了分析。在各轮调查中,所有年龄段的平均体重指数从30.2逐渐增加到31.0。即使在代谢健康的肥胖个体中,抑郁症和行动能力受损也非常普遍。虽然大多数肥胖者至少有一种可检测到的异常,但所呈现的合并症存在很大异质性。最常见的EOSS类别在医学维度为2期(90.1%),在功能和心理维度为1期(分别为75.1%和62.9%)。肥胖相关合并症的患病率随年龄增加,但在所有调查中相似。在两性中,随着年龄和体重指数的增加,代谢健康肥胖的可能性降低。
在墨西哥,肥胖合并症的患病率随时间一直保持稳定,但随年龄增加。肥胖患病率的上升和人口老龄化将给人群和卫生系统带来额外负担。